STROMBAFORT 10 mg tablets BALKAN PHARMACEUTICALS
STROMBAFORT 10mg Review:
NAME OF THE MEDICINAL PRODUCT
1 tablet contains: active substance stanozolol 10 mg or 50 mg; magnesium stearate excipients, crospovidone (Kollidon CL), Ludipress (lactose, polyvidone, crospovidone).
Film-coated tablet White or white yellow, square-shaped tablets, upper and lower flat and flat edges on one side with a dividing line and print (“BP”) and on the other side with the inscription “10” or “50” corresponding to the 10 mg and 50 mg doses, the lateral surface rounded edges.
Strombafort is an anabolic steroid. It stimulates the anabolic processes and inhibits the catabolic ones, caused by glucocorticoids. It leads to muscle growth, fat loss reduction, relieves tissue trophic, favors calcium deposition in bone, and retains auxotrophic, gossypol, sodium, potassium and water in the body. Hematopoietic action is determined by increased erythropoietin synthesis. The ant allergic action is determined by the increase in the iron level of the C1 fraction of the complement. Androgenic (moderate) action can contribute to the development of male sex.
The deficiencies of protein synthesis, cases of various genesis, trauma, burns, pre- and post-operative periods, infectious diseases and irradiation, renal and adrenal insufficiency, muscular dystrophy, osteoporosis, negative nitrate balance in corticosteroids, – and aplastic. Prophylactic for decreasing the frequency and severity of the hereditary angioedema. Adjuvant in the treatment of tuberculosis, osteomyelitis, bronchial asthma, hepatitis.
DOSAGE AND ADMINISTRATION
Adult’s Initial dose 10-20 mg / day. Maintenance dose 10-50 mg / day. To reduce the frequency and severity of hereditary angioedema, doses are adjusted individually depending on the clinical response. The initial dose contains 2 mg 3 times a day. When a favorable response is obtained, the dose is gradually reduced over a period of 1 to 3 months to 2 mg per day.
Hypersensitivity to the preparation, prostate cancer breast cancer in men breast carcinoma in women with hypercalcemia, CPI, severe atherosclerosis, liver and kidney failure, acute and chronic prostatitis, pregnancy and lactation.